Edwin is a healthcare journalist with a passion for data and analysis. He graduated with a master's degree in biomedical sciences and spent some time in postgraduate research before moving into journalism. Edwin's skills in data science and scientific analysis allow him to identify trends, develop insights, and tell compelling stories using data.
Latest from Edwin Elmhirst
A pilot partnership between the FDA and Canada's Medical Devices Programme has been so successful the two agencies will talk this week about how to expand it.
A-Fem Medical has filed a patent application to the US Patent Office for its RapidSense technology. The technology provides information for a range of medical tests, including a home pregnancy test the company is developing.
This is an amazing description. Description text goes here.
The second instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on blood malignancies, skin conditions and generalized cardiovascular disease.
Revenues from Rx and OTC pharmaceuticals are returning to the normal annual growth patterns seen during the past decade – the COVID-affected years excepted. In a 3-part series, In Vivo analyzes the market dynamics that support this trend, giving forecasts for individual therapy areas for 2025. This article focuses on the top three therapy areas by growth.
Last year, In Vivo spotlighted some of biopharma’s most highly valued yet unpartnered assets. Now it’s time to see if deals have been struck and review how NPVs have changed.